Search | Clinical Trials Finder

Conditions: Opioid-Related Disorders
Interventions: AV411, Placebo (PCB); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
Interventions: OriCAR-017; Drug
Lead sponsor: OriCell Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sarcoma, Oral Mucositis
Interventions: Caphosol, Baking Soda; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: [225Ac]Ac-FL-020, Blood samples for PK, [111In]In-FL-020, Blood and urine samples collection, SPECT/CT images; Drug · Procedure
Lead sponsor: Full-Life Technologies UK Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Duarte, California • Irvine, California • Stanford, California + 2 more

Conditions: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Interventions: WEF-001; Drug
Lead sponsor: Auricula Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: HER-2 Positive Advanced Solid Tumors
Interventions: D3L-001; Biological
Lead sponsor: D3 Bio (Wuxi) Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Stanford, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions: activated recombinant human factor VII, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Psychological Distress, Recidivism
Interventions: Three Principles Counseling; Behavioral
Lead sponsor: Pacific University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Hillsboro, Oregon

Conditions: Central Nervous System
Interventions: perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 23
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Gulf Breeze, Florida + 20 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: transcranial direct current stimulation Soterix REMOTE 1x1 miniCT; Device
Lead sponsor: Morgan State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
Interventions: CC-223; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more

Conditions: Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
Interventions: BGC515; Drug
Lead sponsor: BridGene Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post-Traumatic Stress Disorder in Adolescence, PTSD - Post Traumatic Stress Disorder, PTSD and Trauma-related Symptoms, Pregnancy and PTSD
Interventions: Written Exposure Therapy; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 15 Years to 24 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Insomnia, Sleeplessness, Transient Insomnia, Nonorganic Insomnia, Chronic Insomnia
Interventions: ACT Intervention, Waitlist; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Breast Cancer
Interventions: ActiveHeal; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Chronic Mechanical Lower Back Pain, Lower Back Pain, Chronic Lower Back Pain
Interventions: Umbilical Cord Blood-Derived Stem Cells and Exosomes, Placebo IV; Biological · Other
Lead sponsor: Adia Med of Winter Park LLC; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Winter Park, Florida

Conditions: Necrotizing Enterocolitis
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 2 Weeks to 8 Weeks
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Little Rock, Arkansas • New Haven, Connecticut • Tampa, Florida + 4 more

Conditions: Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer, Leukemia
Interventions: Enhanced Mindfulness Intervention, Psychoeducation; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 24 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: INNO-206; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more

Conditions: Tobacco Use Cessation
Interventions: web-based video game (Quit IT), Questionnaires, Salvia sample; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions: PF-08634404, Ipilimumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Los Angeles, California • Pasadena, California • Land O' Lakes, Florida + 13 more

Conditions: Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Cancer
Interventions: AbGn-107; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Phoenix, Arizona • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Hodgkin Lymphoma
Interventions: Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions: PLX51107; Drug
Lead sponsor: Plexxikon; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more

Search by objective public record fields.

Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Caphosol in Sarcoma Patients With Mucositis

Study With [225Ac]Ac-FL-020 in mCRPC Participants

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Three-Principles Approach for Incarcerated Adults

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

Neural and Immune Correlates of CIPN and Possible Analgesic Effect of Non-invasive Motor Cortex Stimulation

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Empowering Perinatal Adolescents Through Writing

Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)

A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework

Adia Med of Winter Park LLC Lower Back Pain Research Study

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Quit IT: Preliminary Testing of a Web-based, 3D Coping Skills Game to Increase Quitting Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

A Study of PLX51107 in Advanced Malignancies